Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

Table 5 Univariate and multivariate analysis of progression-free survival in advanced human epidermal growth factor receptor 2-positive gastric cancer

Factor	n = 104	mPFS (months)	Univariate analysis			Multivariate analysis
			HR	95%CI	P value	HR	95%CI	P value
Gender			0.961	0.558-1.657	0.894
Male	81	7.8
Female	23	7.4
Age (years)			0.746	0.469-1.181	0.203
< 65	57	6.6
≥ 65	47	9.1
ECOG score			1.972	1.208-3.199	0.005	2.014	1.231-3.265	0.004
0	42	11.6
1-2	62	6.7
Tumor location			1.048	0.663-1.652	0.847
Stomach	47	7.9
Gastroesophageal Junction	57	7.6
Surgical status			1.299	0.765-2.214	0.335
Yes	25	6.6
No	79	7.8
Liver metastasis			1.125	0.708-1.767	0.623
Yes	45	6.8
No	59	7.9
Peritoneal metastasis			3.782	2.256-6.343	< 0.001	3.767	2.249-6.285	< 0.001
Yes	32	4.2
No	72	9.3
HER-2 expression			0.779	0.485-1.248	0.300
IHC2 + (ISH positive)	38	7.6
IHC3 +	66	7.9
PD-L1 expression			1.847	1.159-2.874	0.046	2.158	1.325-3.131	0.017
Positive (CPS ≥ 1%)	45	8.9
Negative (CPS < 1%)	59	4.5
Chemotherapy regimen			1.592	1.003-2.569	0.049	1.731	1.074-2.775	0.026
Combined immunotherapy	50	9.3
Non-combined Immunotherapy	54	6.7

ECOG: Eastern Cooperative Oncology Group; HER-2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; ISH: In situ hybridization; PD-L1: Programmed death-ligand 1; CPS: Combined positive score; mPFS: Median progression-free survival; HR: Hazard ratio; CI: Confidence interval.